K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 4 172 JPY -1.18% Market Closed
Market Cap: 158B JPY
Have any thoughts about
Kaken Pharmaceutical Co Ltd?
Write Note

Kaken Pharmaceutical Co Ltd
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kaken Pharmaceutical Co Ltd
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Other Equity
ÂĄ1.3B
CAGR 3-Years
112%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Other Equity
ÂĄ2.1T
CAGR 3-Years
66%
CAGR 5-Years
75%
CAGR 10-Years
17%
Daiichi Sankyo Co Ltd
TSE:4568
Other Equity
ÂĄ245.7B
CAGR 3-Years
29%
CAGR 5-Years
22%
CAGR 10-Years
5%
Otsuka Holdings Co Ltd
TSE:4578
Other Equity
ÂĄ237.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
19%
Chugai Pharmaceutical Co Ltd
TSE:4519
Other Equity
ÂĄ2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
6%
Astellas Pharma Inc
TSE:4503
Other Equity
ÂĄ463.3B
CAGR 3-Years
41%
CAGR 5-Years
37%
CAGR 10-Years
11%
No Stocks Found

Kaken Pharmaceutical Co Ltd
Glance View

Market Cap
158B JPY
Industry
Pharmaceuticals

Founded in 1948, Kaken Pharmaceutical Co., Ltd. is a prominent player in Japan's pharmaceutical landscape, seamlessly blending tradition with innovation. The company's journey began amidst post-war economic rebuilding, initially catering to the nation's healthcare needs with basic medicines. Over the years, it has carved out a niche for itself, specializing in the development, manufacturing, and commercialization of a wide range of pharmaceutical products. Kaken's focus areas include dermatology, orthopedics, and surgery, with a strong emphasis on treatments for fungal infections and inflammation management. This specialization has propelled the company into a position of leadership, especially in the dermatology market, where its expertise in topical formulations excels. Kaken Pharmaceutical monetizes its ventures primarily through the sale of prescription and over-the-counter drugs, leveraging a robust distribution network that extends its reach across Japan and international markets. The company continually reinvests in research and development to sustain its competitive edge, regularly introducing innovative therapies that address unmet medical needs. While pharmaceuticals remain its core revenue stream, Kaken also generates income from its chemical businesses, which include agrochemicals and animal health products, further diversifying its portfolio. By maintaining a balanced blend of traditional pharmaceutical sales and chemical product lines, Kaken ensures steady financial footing while advancing health solutions for a global audience.

Intrinsic Value
1 867.16 JPY
Overvaluation 55%
Intrinsic Value
Price
K

See Also

What is Kaken Pharmaceutical Co Ltd's Other Equity?
Other Equity
1.3B JPY

Based on the financial report for Sep 30, 2024, Kaken Pharmaceutical Co Ltd's Other Equity amounts to 1.3B JPY.

What is Kaken Pharmaceutical Co Ltd's Other Equity growth rate?
Other Equity CAGR 3Y
112%

Over the last year, the Other Equity growth was 712%. The average annual Other Equity growth rates for Kaken Pharmaceutical Co Ltd have been 112% over the past three years .

Back to Top